| CPC A61K 39/145 (2013.01) [A61K 8/553 (2013.01); A61K 9/0014 (2013.01); A61K 31/16 (2013.01); A61K 31/685 (2013.01); A61K 39/215 (2013.01); A61K 47/544 (2017.08); C12N 7/00 (2013.01); C12Q 1/70 (2013.01); G01N 33/948 (2013.01); A61K 2039/55511 (2013.01); C12N 2760/16034 (2013.01); C12N 2770/20034 (2013.01)] | 15 Claims |
|
1. A method for improving an immune response to an influenza virus, comprising:
administering an adjuvant comprising miltefosine to a subject at or near a site of vaccination on the subject; and
introducing an influenza vaccine at the vaccination site, the influenza vaccine comprising a vaccinating influenza species,
wherein the adjuvant is selected to provide miltefosine in a quantity sufficient to increase the immune response relative to a vaccinated subject that has not been administered the adjuvant;
wherein the adjuvant comprising miltefosine is administered immediately prior to vaccination or from about 5 minutes to about 48 hours prior to vaccination; and
wherein the adjuvant comprising miltefosine is administered by intramuscular injection, intradermal injection, or topical application.
|